Erasmus MC

erasmusmc.nl

Erasmus MC is the largest and most versatile of the eight university medical centers in the Netherlands. At Erasmus MC you create your own opportunities. A conscious choice for work that matters, both nationally and internationally, at the heart of our multicultural home base of Rotterdam. Working from the heart. Together with people, for people.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

news image

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More

MedTech, Industrial Impact

JANUX THERAPEUTICS SUBMITS IND APPLICATION FOR JANX008

Janux | December 29, 2022

news image

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop a diverse pipeline of novel immunotherapies. On December 27, 2022, the company announced that it had submitted an investigational new drug (IND) application for JANX008 to U.S. Food and Drug Administration, an EGFR-TRACTr in (SCCHN). The company is pleased to announce its second IND. It consid...

Read More

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

news image

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

news image

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More
news image

Medical

OLIX PHARMACEUTICALS SUBSIDIARY MCUREX ANNOUNCES MRNA TECHNOLOGY COLLABORATION WITH TOOLGEN FOR RARE EYE DISEASE

OliX | June 20, 2022

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics, today announced that the Company’s subsidiary mCureX Therapeutics, Inc. has recently signed a contract for joint research with ToolGen, Inc. to advance the development of gene therapy for rare eye diseases, leveraging mCureX’s mRNA technology. mCureX, specializing in mRNA vaccines and therapeutics, and ToolGen, having expertise in therapeutic gene-editing technologies, have been in active discussions...

Read More
news image

MedTech, Industrial Impact

JANUX THERAPEUTICS SUBMITS IND APPLICATION FOR JANX008

Janux | December 29, 2022

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop a diverse pipeline of novel immunotherapies. On December 27, 2022, the company announced that it had submitted an investigational new drug (IND) application for JANX008 to U.S. Food and Drug Administration, an EGFR-TRACTr in (SCCHN). The company is pleased to announce its second IND. It consid...

Read More
news image

Cell and Gene Therapy

DELFI DIAGNOSTICS SELECTED AS THE LIQUID BIOPSY PARTNER FOR 4-IN-THE-LUNG-RUN: A LARGE-SCALE EUROPEAN LUNG CANCER SCREENING STUDY

Delfi Diagnostics | September 12, 2022

Delfi Diagnostics, a pioneering developer of a new class of high-performance, accessible liquid biopsy tests for early cancer detection and monitoring, has been selected as the liquid lung cancer biopsy partner in Europe's multi-national, randomized, prospective lung cancer screening trial known as 4-IN-THE-LUNG-RUN, or 4ITLR. Through 4ITLR, European investigators are studying how often – every year, or every other year – individuals should get screened if their in...

Read More
news image

Industrial Impact, Medical

GENPREX STRENGTHENS DIABETES GENE THERAPY PROGRAM WITH LICENSE OF ADDITIONAL TECHNOLOGY FROM UNIVERSITY OF PITTSBURGH

Genprex, Inc. | December 16, 2022

Genprex, Inc. a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Pittsburgh, granting Genprex a worldwide, exclusive license to certain patent applications and related technology and a worldwide, non-exclusive license to use certain related know-how, all related to modulating autoimmunity in Type 1 diabetes by using gene ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us